NovaBridge Biosciences (NBP) Net Margin (2023)
NovaBridge Biosciences (NBP) reported Net Margin of 10557.46% for Q3 2023, up 127.31% quarter-over-quarter from 38657.86% in Q2 2023.
NovaBridge Biosciences (NBP) Net Margin (2023) Analysis & Trends
NovaBridge Biosciences (NBP) has 1 years of Net Margin data on file, last reported at 10557.46% in Q3 2023.
- Net Margin for Q3 2023 came in at 10557.46%, changed N/A year-over-year; the trailing twelve-month figure through Dec 2023 was 1425.47% (changed N/A YoY), and the FY2023 annual result was 32664.4%, down 922623.0% from the prior year.
- Net Margin improved to 10557.46% in Q3 2023 per NBP's latest filing, from 38657.86% in the prior quarter.
- Over five years, Net Margin peaked at 10557.46% in Q3 2023 and troughed at 38657.86% in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 0.82% |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 34.53% |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | - |
| 10 | NovaBridge Biosciences | 328.19 Mn | 117.34 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2023 | 10,557.46% |
| Jun 30, 2023 | -38,657.86% |